What is Teva Pharm's earnings per share (EPS)?

Teva Pharm (TEVA) reported diluted earnings per share of $1.21 for fiscal year 2025. This represents a 183.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Teva Pharm Financials

TEVA

FY2025 annual

Revenue $17.3B +4.3% YoY

Net Income $1.4B +186.0% YoY

EPS (Diluted) $1.21 +183.4% YoY

Free Cash Flow $1.1B +53.3% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 29, 2026 Currency USD FYE December

Teva Pharm (TEVA) reported $17.3B in revenue for fiscal year 2025, up 4.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TEVA FY2025 2026-07-29

Margin expansion and low capital intensity let Teva turn a modestly growing revenue base into a much stronger profit-and-cash machine.

FY2023-FY2024 net losses still turned into positive free cash flow because depreciation and amortization stayed above $1.0B while capex held near $500M. By FY2025, a gross margin step-up to 51.8% and operating margin rebound to 12.5% let that same cash engine finally show up in reported profit.

The balance sheet is still doing little buffering: current ratio stayed near 1.0x in FY2024-FY2025 while debt to equity stayed above 4.0x even after equity recovered. That leaves little room for operating stumbles or working-capital surprises.

With goodwill still at $16.0B versus total equity of $7.9B, a large part of the asset base is intangible rather than a hard capital cushion. That helps explain why leverage can still look elevated even when annual cash generation is positive.

Financial Health Signals

Financial Health Score 35/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Teva Pharm's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Teva Pharm has an operating margin of 12.5%, meaning the company retains $13 of operating profit per $100 of revenue. This results in a moderate score of 43/100, indicating healthy but not exceptional operating efficiency. This is up from -1.8% the prior year.

Growth

Teva Pharm's revenue grew a modest 4.3% year-over-year to $17.3B. This slow but positive growth earns a score of 48/100.

Leverage

Teva Pharm has elevated debt relative to equity (D/E of 4.15), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 14/100, reflecting increased financial risk.

Liquidity

Teva Pharm's current ratio of 1.04 is below the typical benchmark, resulting in a score of 20/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

Teva Pharm has a free cash flow margin of 6.7%, earning a moderate score of 51/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Teva Pharm's ROE of 17.8% shows moderate profitability relative to equity, earning a score of 36/100. This is up from -30.5% the prior year.

Altman Z-Score Distress

0.95

Teva Pharm scores 0.95, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($44.2B) relative to total liabilities ($32.8B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

7/8

Teva Pharm passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.17x

For every $1 of reported earnings, Teva Pharm generates $1.17 in operating cash flow ($1.6B OCF vs $1.4B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Adequate

2.35x

Teva Pharm earns $2.35 in operating income for every $1 of interest expense ($2.2B vs $916.0M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$17.3B

YoY+4.3%

5Y CAGR+0.7%

10Y CAGR-1.3%

Teva Pharm generated $17.3B in revenue in fiscal year 2025. This represents an increase of 4.3% from the prior year.

EBITDA

$3.2B

YoY+317.9%

10Y CAGR-3.8%

Teva Pharm's EBITDA was $3.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 317.9% from the prior year.

Net Income

$1.4B

YoY+186.0%

10Y CAGR-1.2%

Teva Pharm reported $1.4B in net income in fiscal year 2025. This represents an increase of 186.0% from the prior year.

EPS (Diluted)

$1.21

YoY+183.4%

Teva Pharm earned $1.21 per diluted share (EPS) in fiscal year 2025. This represents an increase of 183.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$1.1B

YoY+53.3%

5Y CAGR+12.5%

10Y CAGR-13.3%

Teva Pharm generated $1.1B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 53.3% from the prior year.

Cash & Debt

$3.6B

YoY+7.8%

5Y CAGR+10.3%

10Y CAGR-6.5%

Teva Pharm held $3.6B in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

1.15B

YoY+1.4%

5Y CAGR+1.0%

Teva Pharm had 1.15B shares outstanding in fiscal year 2025. This represents an increase of 1.4% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

51.8%

YoY+3.1pp

5Y CAGR+5.4pp

10Y CAGR-6.0pp

Teva Pharm's gross margin was 51.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.1 percentage points from the prior year.

Operating Margin

12.5%

YoY+14.3pp

5Y CAGR+33.9pp

10Y CAGR-4.6pp

Teva Pharm's operating margin was 12.5% in fiscal year 2025, reflecting core business profitability. This is up 14.3 percentage points from the prior year.

Net Margin

8.2%

YoY+18.1pp

5Y CAGR+32.1pp

10Y CAGR+0.1pp

Teva Pharm's net profit margin was 8.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 18.1 percentage points from the prior year.

Return on Equity

17.8%

YoY+48.3pp

5Y CAGR+57.6pp

10Y CAGR+12.5pp

Teva Pharm's ROE was 17.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 48.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$1.0B

YoY+1.5%

5Y CAGR+0.3%

10Y CAGR+40.0%

Teva Pharm invested $1.0B in research and development in fiscal year 2025. This represents an increase of 1.5% from the prior year.

Capital Expenditures

$501.0M

YoY+0.6%

5Y CAGR-2.8%

10Y CAGR-4.2%

Teva Pharm invested $501.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 0.6% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

TEVA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

TEVA quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$14.1B	$17.3B+4.3%	$16.5B+4.4%	$15.8B+6.2%	$14.9B-6.0%	$15.9B-4.7%	$16.7B-1.4%	$16.9B-7.6%	$18.3B-16.4%	$21.9B-0.2%	$21.9B+11.5%	$19.7B-3.1%	$20.3B-0.2%	$20.3B0.0%	$20.3B+10.9%	$18.3B
Cost of Revenue	N/A	$8.3B-1.9%	$8.5B+3.4%	$8.2B+3.1%	$8.0B-4.0%	$8.3B-7.3%	$8.9B-4.5%	$9.4B-6.3%	$10.0B-11.2%	$11.2B+11.9%	$10.0B+21.1%	$8.3B-10.0%	$9.2B-4.1%	$9.6B-0.6%	$9.7B+9.9%	$8.8B
Gross Profit	N/A	$8.9B+10.8%	$8.1B+5.5%	$7.6B+9.6%	$7.0B-8.2%	$7.6B-1.7%	$7.7B+2.5%	$7.5B-9.1%	$8.3B-21.8%	$10.6B-10.5%	$11.9B+4.4%	$11.4B+2.7%	$11.1B+3.3%	$10.7B+0.5%	$10.7B+11.9%	$9.5B
R&D Expenses	N/A	$1.0B+1.5%	$998.0M+4.7%	$953.0M+872.4%	$98.0M-89.9%	$967.0M-3.0%	$997.0M-1.3%	$1.0B+786.0%	$114.0M-34.9%	$175.0M-58.5%	$422.0M+1105.7%	$35.0M	$0-100.0%	$5.0M-93.2%	$73.0M+386.7%	$15.0M
SG&A Expenses	N/A	$1.3B+10.9%	$1.2B-0.1%	$1.2B-1.5%	$1.2B+7.4%	$1.1B-6.3%	$1.2B-1.6%	$1.2B-8.2%	$1.3B-10.5%	$1.5B+12.9%	$1.3B-5.5%	$1.4B+11.8%	$1.2B-1.8%	$1.2B+0.1%	$1.2B+32.8%	$932.0M
Operating Income	N/A	$2.2B+811.9%	-$303.0M-170.0%	$433.0M+119.7%	-$2.2B-228.0%	$1.7B+148.0%	-$3.6B-706.3%	-$443.0M+72.9%	-$1.6B+90.6%	-$17.5B-911.7%	$2.2B-35.7%	$3.4B-15.2%	$4.0B+139.6%	$1.6B-25.2%	$2.2B-29.1%	$3.1B
Interest Expense	N/A	$916.0M-8.6%	$1.0B-2.6%	$1.0B+10.6%	$930.0M+4.4%	$891.0M-1.1%	$901.0M+9.6%	$822.0M-10.7%	$920.0M+5.1%	$875.0M+60.3%	$546.0M+102.2%	$270.0M-10.0%	$300.0M-4.5%	$314.0M-11.5%	$355.0M+51.7%	$234.0M
Income Tax	N/A	-$180.0M-126.6%	$676.0M+9757.1%	-$7.0M+98.9%	-$643.0M-404.7%	$211.0M+225.6%	-$168.0M+39.6%	-$278.0M-42.6%	-$195.0M+89.9%	-$1.9B-471.0%	$521.0M-17.8%	$634.0M+7.3%	$591.0M+1474.4%	-$43.0M+68.6%	-$137.0M-207.9%	$127.0M
Net Income	N/A	$1.4B+186.0%	-$1.6B-193.2%	-$559.0M+77.1%	-$2.4B-686.6%	$417.0M+110.5%	-$4.0B-299.4%	-$999.0M+53.5%	-$2.1B+86.8%	-$16.3B-5043.8%	$329.0M-79.3%	$1.6B-48.0%	$3.1B+140.7%	$1.3B-35.4%	$2.0B-28.9%	$2.8B
EPS (Diluted)	$0.60	$1.21+183.4%	-$1.45-190.0%	-$0.50+77.3%	-$2.20-678.9%	$0.38+110.4%	-$3.64-300.0%	-$0.91+61.3%	-$2.35+85.5%	-$16.26	$0.07	$1.82-48.9%	$3.56+138.9%	$1.49-33.8%	$2.25-27.2%	$3.09

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$4.1B+4.0%	$4.0B+165.5%	$1.5B-66.5%	$4.5B+7.3%	$4.2B+7.3%	$3.9B-8.0%	$4.2B-2.4%	$4.3B
Cost of Revenue	$2.0B-1.1%	$2.0B	N/A	$2.2B+4.9%	$2.1B+3.0%	$2.0B-4.5%	$2.1B-3.3%	$2.2B
Gross Profit	$2.2B+9.2%	$2.0B	N/A	$2.3B+9.6%	$2.1B+12.0%	$1.9B-11.5%	$2.1B-1.3%	$2.1B
R&D Expenses	$970.0M+336.9%	$222.0M	N/A	$256.0M+4.9%	$244.0M-1.2%	$247.0M0.0%	$247.0M+2.9%	$240.0M
SG&A Expenses	$317.0M+4.3%	$304.0M	N/A	$317.0M+3.9%	$305.0M+2.7%	$297.0M-1.7%	$302.0M+1.3%	$298.0M
Operating Income	-$231.0M-135.4%	$652.0M	N/A	$882.0M+93.8%	$455.0M-12.3%	$519.0M+1889.7%	-$29.0M+43.1%	-$51.0M
Income Tax	$121.0M+80.6%	$67.0M	N/A	$214.0M+374.4%	-$78.0M-205.4%	$74.0M+155.2%	$29.0M-58.0%	$69.0M
Net Income	-$576.0M-256.1%	$369.0M	N/A	$433.0M+53.5%	$282.0M+31.8%	$214.0M+198.6%	-$217.0M+50.3%	-$437.0M
EPS (Diluted)	-$0.49-258.1%	$0.31-24.4%	$0.41+10.8%	$0.37+54.2%	$0.24+33.3%	$0.18+194.7%	-$0.19+51.3%	-$0.39

Not reported in any period shown, so not listed: Interest Expense.

TEVA Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

TEVA quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$40.7B+3.6%	$39.3B-9.6%	$43.5B-1.2%	$44.0B-7.7%	$47.7B-5.9%	$50.6B-11.9%	$57.5B-5.3%	$60.7B-14.1%	$70.6B-24.1%	$93.1B+71.6%	$54.2B+16.8%	$46.4B-2.3%	$47.5B-6.1%	$50.6B+0.9%	$50.1B
Current Assets	$13.9B+11.1%	$12.6B+0.5%	$12.5B+3.6%	$12.1B-4.2%	$12.6B-3.3%	$13.0B-3.4%	$13.5B-2.4%	$13.8B-10.3%	$15.4B-10.7%	$17.2B-6.4%	$18.4B+27.8%	$14.4B+4.9%	$13.7B-16.1%	$16.4B+13.2%	$14.5B
Cash & Equivalents	$3.6B+7.8%	$3.3B+2.3%	$3.2B+15.2%	$2.8B+29.4%	$2.2B-0.6%	$2.2B+10.2%	$2.0B+10.8%	$1.8B+85.0%	$963.0M-2.5%	$988.0M-85.8%	$6.9B+212.0%	$2.2B+114.5%	$1.0B-63.9%	$2.9B+162.7%	$1.1B
Inventory	$3.2B+5.7%	$3.0B-25.2%	$4.0B+4.9%	$3.8B+0.4%	$3.8B-13.3%	$4.4B-0.4%	$4.4B-6.5%	$4.7B-3.9%	$4.9B-0.6%	$5.0B+24.9%	$4.0B-9.3%	$4.4B-13.5%	$5.1B-8.2%	$5.5B+9.8%	$5.0B
Accounts Receivable	$3.7B+21.2%	$3.1B-10.2%	$3.4B-7.8%	$3.7B-18.4%	$4.5B-1.1%	$4.6B-19.3%	$5.7B-2.5%	$5.8B-18.3%	$7.1B-5.3%	$7.5B+40.6%	$5.3B-1.1%	$5.4B+1.3%	$5.3B-4.2%	$5.6B-10.3%	$6.2B
Goodwill	$16.0B0.0%	$16.0B-6.9%	$17.2B0.0%	$17.2B-2.6%	$17.6B-14.5%	$20.6B-17.0%	$24.8B-0.3%	$24.9B-12.3%	$28.4B-36.0%	$44.4B+133.4%	$19.0B+3.4%	$18.4B-3.0%	$19.0B+0.7%	$18.9B+3.1%	$18.3B
Total Liabilities	$32.8B-2.3%	$33.6B-4.9%	$35.4B-0.2%	$35.4B-2.8%	$36.4B-8.0%	$39.6B-6.7%	$42.4B-5.5%	$44.9B-13.5%	$51.9B-10.7%	$58.1B+138.9%	$24.3B+5.4%	$23.1B-7.3%	$24.9B-10.3%	$27.7B-0.2%	$27.8B
Current Liabilities	$13.5B+5.2%	$12.8B+4.5%	$12.2B+6.8%	$11.5B+4.0%	$11.0B-16.2%	$13.2B-3.7%	$13.7B-4.5%	$14.3B-20.1%	$17.9B-3.1%	$18.5B+42.2%	$13.0B+5.8%	$12.3B+2.7%	$12.0B-7.2%	$12.9B-5.8%	$13.7B
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$28.8B-11.4%	$32.5B+289.1%	$8.4B-2.4%	$8.6B-23.5%	$11.2B-20.8%	$14.1B+24.1%	$11.4B
Total Equity	$7.9B+47.2%	$5.4B-28.4%	$7.5B-3.8%	$7.8B-24.1%	$10.3B+2.5%	$10.0B-28.2%	$14.0B-5.0%	$14.7B-15.3%	$17.4B-47.9%	$33.3B+12.0%	$29.8B+27.7%	$23.3B+3.3%	$22.6B-0.9%	$22.8B+2.6%	$22.2B
Retained Earnings	-$13.8B+9.3%	-$15.2B-12.1%	-$13.5B-4.3%	-$13.0B-23.2%	-$10.5B+3.8%	-$10.9B-57.4%	-$7.0B-16.8%	-$6.0B-56.7%	-$3.8B-127.9%	$13.6B-8.4%	$14.9B+2.9%	$14.4B+15.2%	$12.5B+1.5%	$12.3B+9.4%	$11.3B

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$39.9B-0.5%	$40.0B-1.7%	$40.7B+2.2%	$39.9B-0.7%	$40.1B+4.5%	$38.4B-2.3%	$39.3B-5.8%	$41.8B
Current Assets	$13.8B+0.4%	$13.7B-1.7%	$13.9B+9.5%	$12.7B+0.9%	$12.6B+9.5%	$11.5B-8.2%	$12.6B+1.9%	$12.3B
Cash & Equivalents	$3.7B-2.3%	$3.7B+5.2%	$3.6B+61.4%	$2.2B+1.9%	$2.2B+27.3%	$1.7B-48.6%	$3.3B-0.6%	$3.3B
Inventory	$3.2B+1.4%	$3.2B-0.1%	$3.2B-4.3%	$3.3B-5.0%	$3.5B+7.7%	$3.2B+8.0%	$3.0B-24.0%	$4.0B
Accounts Receivable	$3.5B+2.9%	$3.4B-8.5%	$3.7B-2.7%	$3.8B+6.9%	$3.6B+5.3%	$3.4B+10.6%	$3.1B-11.6%	$3.5B
Goodwill	$15.8B+0.1%	$15.8B-1.1%	$16.0B+0.3%	$15.9B0.0%	$15.9B+3.0%	$15.5B-3.3%	$16.0B-0.8%	$16.1B
Total Liabilities	$32.1B+0.9%	$31.8B-3.1%	$32.8B+0.7%	$32.6B-2.1%	$33.3B+3.6%	$32.1B-4.3%	$33.6B-5.0%	$35.4B
Current Liabilities	$15.6B+15.6%	$13.5B+0.6%	$13.5B+17.1%	$11.5B-3.1%	$11.9B+6.3%	$11.2B-12.8%	$12.8B-7.3%	$13.8B
Total Equity	$7.8B-5.8%	$8.2B+4.0%	$7.9B+9.1%	$7.3B+6.2%	$6.8B+9.0%	$6.3B+16.5%	$5.4B-11.4%	$6.1B
Retained Earnings	-$14.0B-4.3%	-$13.4B+2.7%	-$13.8B+3.4%	-$14.2B+3.0%	-$14.7B+1.9%	-$15.0B+1.4%	-$15.2B-1.5%	-$15.0B

Not reported in any period shown, so not listed: Long-Term Debt.

TEVA Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

TEVA quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	$1.9B	$1.6B+32.2%	$1.2B-8.8%	$1.4B-14.0%	$1.6B+99.2%	$798.0M-34.4%	$1.2B+62.6%	$748.0M-69.4%	$2.4B+9.9%	$2.2B-57.4%	$5.2B-5.7%	$5.5B+8.1%	$5.1B+58.4%	$3.2B-29.2%	$4.6B+10.6%	$4.1B
Capital Expenditures	$550.0M	$501.0M+0.6%	$498.0M-5.3%	$526.0M-4.0%	$548.0M-2.5%	$562.0M-2.8%	$578.0M+10.1%	$525.0M-19.4%	$651.0M-25.5%	$874.0M-3.0%	$901.0M+16.7%	$772.0M-16.9%	$929.0M-9.9%	$1.0B-6.6%	$1.1B+4.8%	$1.1B
Free Cash Flow	$1.3B	$1.1B+53.3%	$749.0M-11.0%	$842.0M-19.2%	$1.0B+341.5%	$236.0M-63.0%	$638.0M+186.1%	$223.0M-87.6%	$1.8B+32.9%	$1.4B-68.8%	$4.3B-9.4%	$4.8B+13.6%	$4.2B+90.3%	$2.2B-36.4%	$3.5B+12.6%	$3.1B
Investing Cash Flow	$38.0M	$737.0M-6.9%	$792.0M-18.2%	$968.0M+47.6%	$656.0M-56.9%	$1.5B+76.5%	$863.0M-36.3%	$1.4B-27.4%	$1.9B-45.9%	$3.4B+109.6%	-$35.7B-542.2%	-$5.6B-283.8%	-$1.4B-26.4%	-$1.1B-1.1%	-$1.1B+85.1%	-$7.6B
Financing Cash Flow	-$401.0M	-$2.2B-20.1%	-$1.8B+6.4%	-$1.9B-28.6%	-$1.5B+31.5%	-$2.2B-15.2%	-$1.9B+2.1%	-$1.9B+42.5%	-$3.4B+41.7%	-$5.8B-122.8%	$25.2B+424.8%	$4.8B+302.3%	-$2.4B+38.8%	-$3.9B-131.4%	-$1.7B-150.3%	$3.3B
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$12.0M-98.7%	$901.0M-30.9%	$1.3B+12.8%	$1.2B-0.1%	$1.2B+6.2%	$1.1B+27.4%	$855.0M+6.9%	$800.0M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$439.0M-12.2%	$500.0M+0.6%	$497.0M-57.2%	$1.2B+29.1%	$899.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$411.0M+1127.5%	-$40.0M-103.5%	$1.2B+213.8%	$369.0M+62.6%	$227.0M+316.2%	-$105.0M-118.3%	$575.0M-17.0%	$693.0M
Capital Expenditures	$104.0M-38.1%	$168.0M+18.3%	$142.0M+4.4%	$136.0M+41.7%	$96.0M-24.4%	$127.0M-1.6%	$129.0M-12.8%	$148.0M
Free Cash Flow	$307.0M+247.6%	-$208.0M-120.5%	$1.0B+336.1%	$233.0M+77.9%	$131.0M+156.5%	-$232.0M-152.0%	$446.0M-18.2%	$545.0M
Investing Cash Flow	-$491.0M-314.4%	$229.0M+38.8%	$165.0M+22.2%	$135.0M-42.8%	$236.0M+17.4%	$201.0M-0.5%	$202.0M-24.6%	$268.0M
Financing Cash Flow	-$1.0M-107.7%	$13.0M-67.5%	$40.0M+108.8%	-$453.0M-7650.0%	$6.0M+100.3%	-$1.7B-158.8%	-$674.0M	$0

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

TEVA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

TEVA quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	51.8%+3.1pp	48.7%+0.5pp	48.3%+1.5pp	46.7%-1.1pp	47.8%+1.5pp	46.4%+1.8pp	44.6%-0.8pp	45.4%-3.2pp	48.6%-5.6pp	54.1%-3.6pp	57.8%+3.2pp	54.5%+1.8pp	52.7%+0.3pp	52.4%+0.5pp	52.0%
Operating Margin	12.5%+14.3pp	-1.8%-4.6pp	2.7%+17.4pp	-14.7%-25.5pp	10.8%+32.3pp	-21.4%-18.8pp	-2.6%+6.3pp	-9.0%+71.0pp	-80.0%-89.8pp	9.8%-7.2pp	17.1%-2.4pp	19.5%+11.4pp	8.1%-2.7pp	10.8%-6.1pp	17.0%
Net Margin	8.2%+18.1pp	-9.9%-6.4pp	-3.5%+12.9pp	-16.4%-19.0pp	2.6%+26.6pp	-23.9%-18.0pp	-5.9%+5.8pp	-11.8%+62.7pp	-74.4%-75.9pp	1.5%-6.6pp	8.1%-7.0pp	15.1%+8.8pp	6.3%-3.4pp	9.7%-5.4pp	15.1%
Return on Equity	17.8%+48.3pp	-30.5%-23.0pp	-7.4%+23.9pp	-31.3%-35.4pp	4.1%+43.9pp	-39.8%-32.6pp	-7.1%+7.5pp	-14.6%+79.1pp	-93.7%-94.7pp	1.0%-4.3pp	5.3%-7.8pp	13.1%+7.5pp	5.6%-3.0pp	8.6%-3.8pp	12.4%
Return on Assets	3.5%+7.6pp	-4.2%-2.9pp	-1.3%+4.3pp	-5.6%-6.4pp	0.9%+8.8pp	-7.9%-6.1pp	-1.7%+1.8pp	-3.5%+19.5pp	-23.0%-23.4pp	0.4%-2.6pp	2.9%-3.6pp	6.6%+3.9pp	2.7%-1.2pp	3.9%-1.6pp	5.5%
Current Ratio	1.04+0.1x	0.980.0x	1.020.0x	1.05-0.1x	1.14+0.2x	0.990.0x	0.980.0x	0.96+0.1x	0.86-0.1x	0.93-0.5x	1.41+0.2x	1.170.0x	1.15-0.1x	1.27+0.2x	1.06
Debt-to-Equity	4.15-2.1x	6.25+1.5x	4.71+0.2x	4.54+1.0x	3.54-0.4x	3.95+0.9x	3.040.0x	3.05+1.4x	1.66+0.7x	0.98+0.7x	0.28-0.1x	0.37-0.1x	0.50-0.1x	0.62+0.1x	0.51
FCF Margin	6.7%+2.1pp	4.5%-0.8pp	5.3%-1.7pp	7.0%+5.5pp	1.5%-2.3pp	3.8%+2.5pp	1.3%-8.5pp	9.8%+3.6pp	6.2%-13.6pp	19.7%-4.5pp	24.3%+3.6pp	20.7%+9.8pp	10.9%-6.2pp	17.1%+0.2pp	16.8%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	52.0%+2.5pp	49.5%	N/A	51.4%+1.1pp	50.3%+2.1pp	48.2%-1.9pp	50.1%+0.6pp	49.6%
Operating Margin	-5.6%-22.0pp	16.4%	N/A	19.7%+8.8pp	10.9%-2.4pp	13.3%+14.0pp	-0.7%+0.5pp	-1.2%
Net Margin	-13.9%-23.2pp	9.3%	N/A	9.7%+2.9pp	6.8%+1.3pp	5.5%+10.6pp	-5.1%+5.0pp	-10.1%
Return on Equity	-7.4%-11.9pp	4.5%	N/A	6.0%+1.8pp	4.1%+0.7pp	3.4%+7.5pp	-4.0%+3.2pp	-7.2%
Return on Assets	-1.5%-2.4pp	0.9%	N/A	1.1%+0.4pp	0.7%+0.1pp	0.6%+1.1pp	-0.5%+0.5pp	-1.1%
Current Ratio	0.88-0.1x	1.010.0x	1.04-0.1x	1.110.0x	1.060.0x	1.03+0.1x	0.98+0.1x	0.89
Debt-to-Equity	4.14+0.3x	3.87-0.3x	4.15-0.3x	4.50-0.4x	4.88-0.3x	5.13-1.1x	6.25+0.4x	5.83
FCF Margin	7.4%+12.6pp	-5.2%-73.0pp	67.7%+62.5pp	5.2%+2.1pp	3.1%+9.1pp	-6.0%-16.5pp	10.5%-2.0pp	12.6%

Similar Companies

United Therapeutics Corp. UTHR

$22.2B

Viatris Inc VTRS

$19.4B

Dr Reddys Labs RDY

$10.2B

Neurocrine Biosciences Inc NBIX

$15.9B

Takeda Pharm TAK

$58.2B

Where Teva Pharm Ranks

Frequently Asked Questions

What is Teva Pharm's annual revenue?

Teva Pharm (TEVA) reported $17.3B in total revenue for fiscal year 2025. This represents a 4.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Teva Pharm's revenue growing?

Teva Pharm (TEVA) revenue grew by 4.3% year-over-year, from $16.5B to $17.3B in fiscal year 2025.

Is Teva Pharm profitable?

Yes, Teva Pharm (TEVA) reported a net income of $1.4B in fiscal year 2025, with a net profit margin of 8.2%.

What is Teva Pharm's EBITDA?

Teva Pharm (TEVA) had EBITDA of $3.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Teva Pharm's gross margin?

Teva Pharm (TEVA) had a gross margin of 51.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Teva Pharm's operating margin?

Teva Pharm (TEVA) had an operating margin of 12.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Teva Pharm's net profit margin?

Teva Pharm (TEVA) had a net profit margin of 8.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Teva Pharm's return on equity (ROE)?

Teva Pharm (TEVA) has a return on equity of 17.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Teva Pharm's free cash flow?

Teva Pharm (TEVA) generated $1.1B in free cash flow during fiscal year 2025. This represents a 53.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Teva Pharm's operating cash flow?

Teva Pharm (TEVA) generated $1.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Teva Pharm's total assets?

Teva Pharm (TEVA) had $40.7B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Teva Pharm's capital expenditures?

Teva Pharm (TEVA) invested $501.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Teva Pharm spend on research and development?

Teva Pharm (TEVA) invested $1.0B in research and development during fiscal year 2025.

How many shares does Teva Pharm have outstanding?

Teva Pharm (TEVA) had 1.15B shares outstanding as of fiscal year 2025.

What is Teva Pharm's current ratio?

Teva Pharm (TEVA) had a current ratio of 1.04 as of fiscal year 2025, which is considered adequate.

What is Teva Pharm's debt-to-equity ratio?

Teva Pharm (TEVA) had a debt-to-equity ratio of 4.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Teva Pharm's return on assets (ROA)?

Teva Pharm (TEVA) had a return on assets of 3.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Teva Pharm's Altman Z-Score?

Teva Pharm (TEVA) has an Altman Z-Score of 0.95, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Teva Pharm's Piotroski F-Score?

Teva Pharm (TEVA) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Teva Pharm's earnings high quality?

Teva Pharm (TEVA) has an earnings quality ratio of 1.17x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Teva Pharm cover its interest payments?

Teva Pharm (TEVA) has an interest coverage ratio of 2.35x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Teva Pharm?

Teva Pharm (TEVA) scores 35 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.